Treatment of schizophrenia requires long-term interventions that address the range of problems that the illness generates. Continuous receipt of antipsychotic medication is the bedrock on which all other interventions for schizophrenia rest and lack of adherence to a consistent medication regimen characterizes many patients over the long-term. The potential benefits of long acting medication that does not require daily self administration has only been available with first generation antipsychotics. In the United States, these medications have generally been reserved for patients who have demonstrated histories of non-compliance and repeated relapse. There is now a long acting form of one of the second-generation ('atypical') antipsychotics - risperidone microspheres. The availability of a medication that does not share either the side effect burden or the stigma associated with old long acting medications represents a major development in the treatment of schizophrenia. Evaluating the impact of the first available long-acting second-generation is therefore timely, innovative, and of considerable public health significance. With such a formative development for our field, it will be particularly important for clinicians and patients alike to acquire information on relapse prevention that is independent of pharmaceutical support in a manner comparable to prior relapse prevention studies of first generation antipsychotic medications. This eight site collaborative R01 proposes to investigate in an effectiveness, """"""""modern-day"""""""" relapse prevention design, whether a long acting second generation medication offers advantages compared to oral second-generation medication. Three hundred four consenting subjects will be randomized to physician's choice oral medication or long acting risperidone, treated for up to two and a half years, and evaluated by masked assessors on measures of psychopathology. Data to be collected will also include time to relapse, level of functioning, service utilization, and medication tolerability. All patients will receive a brief psychoeducational intervention designed to enhance treatment adherence. Even relatively modest delays in relapse and improvement of long term functioning potentially resulting from a long acting second-generation medication can translate into substantial public health benefits. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01MH070010-02
Application #
7174617
Study Section
Special Emphasis Panel (ZMH1-ERB-S (01))
Program Officer
Hsiao, John
Project Start
2006-02-01
Project End
2010-12-31
Budget Start
2007-01-01
Budget End
2007-12-31
Support Year
2
Fiscal Year
2007
Total Cost
$204,094
Indirect Cost
Name
University of Iowa
Department
Psychiatry
Type
Schools of Medicine
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Foster, Adriana; Buckley, Peter; Lauriello, John et al. (2017) Combination Antipsychotic Therapies: An Analysis From a Longitudinal Pragmatic Trial. J Clin Psychopharmacol 37:595-599
Criado, Kristen K; Sharp, William G; McCracken, Courtney E et al. (2017) Overweight and obese status in children with autism spectrum disorder and disruptive behavior. Autism :1362361316683888
Buckley, Peter F; Schooler, Nina R; Goff, Donald C et al. (2015) Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. Schizophr Bull 41:449-59
Hallett, Victoria; Lecavalier, Luc; Sukhodolsky, Denis G et al. (2013) Exploring the manifestations of anxiety in children with autism spectrum disorders. J Autism Dev Disord 43:2341-52
Nurmi, E L; Spilman, S L; Whelan, F et al. (2013) Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies. Transl Psychiatry 3:e274
Scahill, Lawrence; Hallett, Victoria; Aman, Michael G et al. (2013) Brief Report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials. J Autism Dev Disord 43:739-46
McCracken, James T; Aman, Michael G; McDougle, Christopher J et al. (2010) Possible influence of variant of the P-glycoprotein gene (MDR1/ABCB1) on clinical response to guanfacine in children with pervasive developmental disorders and hyperactivity. J Child Adolesc Psychopharmacol 20:1-5
Aman, Michael G; Hollway, Jill A; McDougle, Christopher J et al. (2008) Cognitive effects of risperidone in children with autism and irritable behavior. J Child Adolesc Psychopharmacol 18:227-36
Tierney, Elaine; Aman, Michael; Stout, David et al. (2007) Parent satisfaction in a multi-site acute trial of risperidone in children with autism: a social validity study. Psychopharmacology (Berl) 191:149-57
Lindsay, Ronald L; Eugene Arnold, L; Aman, Michael G et al. (2006) Dietary status and impact of risperidone on nutritional balance in children with autism: a pilot study. J Intellect Dev Disabil 31:204-9

Showing the most recent 10 out of 27 publications